Addyi, marketed as the 'female Viagra,' was approved over a decade ago amid controversy, but it has proven to be only marginally effective with significant side effects. Despite lobbying efforts and expanded indications for older women, the drug's actual benefits are minimal, with only a slight increase in satisfying sexual events, and it remains a poor choice compared to other medications. The article criticizes the drug's approval process and marketing tactics, emphasizing that it is not a safe or effective solution for female sexual desire issues.
The FDA has approved the drug Addyi for treating hypoactive sexual desire disorder in women under 65 who are postmenopausal, expanding its use beyond premenopausal women, with experts discussing its effects, side effects, and alternative approaches for low libido during menopause.
The FDA has approved the use of Addyi, a libido-boosting pill, for women over 65 who are postmenopausal, expanding its previous use for premenopausal women, despite concerns over side effects and effectiveness.
The FDA has approved the use of Addyi, a libido-boosting pill, for women over 65 who have gone through menopause, expanding its previous approval for premenopausal women, despite concerns about side effects and the controversial nature of diagnosing low sexual desire as a medical condition.
The FDA has expanded the approval of the libido drug Addyi to include women over 65 who are postmenopausal, after initial approval for premenopausal women. Despite past concerns over side effects and modest effectiveness, the drug's approval reflects ongoing efforts to address female sexual health issues.
